|Description||Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, is a potent guanylate cyclase activator. Ataciguat has potential to treat diseases associated with increased vascular tone combined with enhanced ROS production.|
|Application||Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, belongs to a new structural class of sGC activators capable of activating the oxidized form of sGC. Ataciguat has been shown to improve endothelial function and to reduce p|
Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. At the moment Phase III clinical trials investigate the ...
An experimental drug as an an activator of sGC in an NO-independent manner (Kd = 3.2 nM).
Plecanatide, also called Trulance, a synthetic analogue of uroguanylin, is a guanylate cyclase-C (GCC) agonist being developed by Synergy Pharmaceuticals for th...
Linaclotide is an oligo-peptide agonist of guanylate cyclase 2C. It can be used for the treatment in adults of constipation-predominant irritable bowel syndrome...
IWP-051 is a soluble guanylate cyclase (sGC) stimulator with EC50 of 290nM. IWP-051 shows >99% plasma protein binding, high permeability, high metabolic stabili...
Vericiguat is a potent guanylate cyclase stimulant under the development of Bayer HealthCare Pharmaceuticals. Direct stimulation of guanylate cyclase is emergin...
BAY 41-2272 is a direct and NO-independent soluble guanylate cyclase (sGC) stimulator.
Ataciguat, formerly referred to as HMR-1766, a novel anthranilic acid derivative, is a potent guanylate cyclase activator. Ataciguat has potential to treat dise...
Linaclotide is a peptide agonist of guanylate cyclase 2C that is undergoing clinical trials for use in treating abdominal pain in patients with irritable bowel ...
BAY-41-8543, with antihypertensive, is a heme-dependent stimulator of NO-independent guanylyl cyclase (sGC). In vivo, BAY 41-8543 decreases blood pressure dose-...